Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT›Acknowledgements

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT · Acknowledgements

Acknowledgements

CC BY 4.0 · National Institute for Health and Care Research · approximately 4 min read

We thank all of the trial participants and the health-care, pharmacy and prison staff at HMP YOI Isis and HM YOI Polmont, as well as pharmacy staff at Forth Valley Royal Hospital, and the staff at King’s Health Partners Clinical Trial Office and the King's Clinical Trial Unit.

Philip Asherson is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, and by a NIHR Senior Investigator award (NF-SI-0616-10040).

Research teams

A huge thank you to all the fantastic research staff who have worked with us over the years: Craig Marsh, Megan Bedding, Laura Giannulli, Megan Mansfield, Caroline Kelly, Lauren Wilson, Clare McCafferty, Grace Williamson, Khuram Khan, Donnie McPherson, Sharon Jakobowitz, Lydia Carter-Mackie and Prajakta Patil.

Contributions of authors

Philip Asherson (https://orcid.org/0000-0003-2667-2254) (Chief Investigator) had overall responsibility for the trial design and trial management.

Lena Johansson (https://orcid.org/0000-0002-4473-1134) (Clinical Trial Manager) co-ordinated the implementation of the trial and day-to-day management, and contributed to the interpretation of the trial findings.

Rachel Holland (https://orcid.org/0000-0002-8630-2821) (Trial Statistician) developed the SAP, prepared DMC reports, completed all analyses and contributed to the interpretation of the trial findings.

Megan Bedding (https://orcid.org/0000-0002-5256-0021) (Research Worker) contributed to data collection, was a TMG member and contributed to the the interpretation of the trial findings.

Andrew Forrester (https://orcid.org/0000-0003-2510-1249) (Co-applicant) contributed to the design and interpretation of the trial findings, and dissemination activities.

Laura Giannulli (https://orcid.org/0000-0002-4182-1820) (Research Worker) contributed to data collection, was a TMG member and contributed to the interpretation of the trial findings.

Ylva Ginsberg (https://orcid.org/0000-0003-1934-376X) (TSC member) contributed to the interpretation of the trial and writing of the final report.

Sheila Howitt (https://orcid.org/0000-0002-2489-2440) (Co-applicant, Research Psychiatrist) contributed to the design, data collection and interpretation of the trial findings.

Imogen Kretzschmar (https://orcid.org/0000-0002-4615-7754) (Research Psychiatrist) was a TMG member and contributed to data collection and the interpretation of the trial findings.

Stephen Lawrie (https://orcid.org/0000-0002-2444-5675) (Co-applicant) contributed to the design and interpretation of the trial findings.

Craig Marsh (https://orcid.org/0000-0003-2149-8189) (Research Psychiatrist), Caroline Kelly (https://orcid.org/0000-0003-4349-5915) (Research Worker), Megan Mansfield (https://orcid.org/0000-0003-2896-3119) (Research Worker), Clare McCafferty (https://orcid.org/0000-0002-3633-2686) (Research Nurse) and Khuram Khan (Research Psychiatrist) contributed to data collection, were TMG members and contributed to the interpretation of the trial findings.

Ulrich Müller-Sedgwick (https://orcid.org/0000-0002-5499-4077) (TSC member) contributed to the interpretation of the trial findings.

John Strang (https://orcid.org/0000-0002-5413-2725) (Co-applicant) contributed to the design and interpretation of the trial findings.

Grace Williamson (https://orcid.org/0000-0002-4618-5819) (Research Placement Student) and Lauren Wilson (https://orcid.org/0000-0001-8817-6788) (Research Placement Student) contributed to data collection, were TMG members and contributed to the interpretation of the trial findings.

Susan Young (https://orcid.org/0000-0002-8494-6949) (Co-applicant) contributed to the design and interpretation of the trial findings and dissemination activities.

Sabine Landau (https://orcid.org/0000-0002-3615-8075) (Statistician and Co-applicant) provided senior statistical support throughout the trial.

Lindsay Thomson (https://orcid.org/0000-0002-0748-6547) (Principle Investigator and Co-applicant) was instrumental in the development of the trial, led the group in Scotland and contributed to analysis and interpretation of the trial findings.

All authors contributed to the writing of the report and had the opportunity to revise it prior to submission.

Publications

Asherson P, Johansson L, Holland R, Fahy T, Forester A, Howitt S, et al. Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II). Trials 2019;20:663.

Asherson P, Johansson L, Holland R, Bedding M, Forrester A, Giannulli L, et al. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study [published online ahead of print June 3 2022]. Br J Psychiatry 2022.

Data-sharing statement

All data-sharing requests should be submitted to the corresponding author for consideration. Access to available anonymised data may be granted, following review. The data set that will be shared will be a pseudo-anonymised data set and will not include date of birth, initials or prison name.

Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people’s patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.

Disclaimers

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the EME programme or the Department of Health and Social Care.

← References

Attribution. Philip Asherson; Lena Johansson; Rachel Holland; Megan Bedding; Andrew Forrester; Laura Giannulli et al. (2022). OROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT. National Institute for Health and Care Research. Copyright © 2022 Asherson et al. This work was produced by Asherson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK581759. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • Acknowledgements

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support